China - China – A biotech company seeks UK cooperation with cellular immunity technology
This is a business opportunity from an overseas buyer. Pitch for the business and explain how your company meets their requirements.
Details
- Opportunity closing date
- 30 June 2016
- Opportunity publication date
- 24 March 2016
- Opportunity type
-
Private Sector
- Industry
- Pharmaceuticals and biotechnology
- Enquiries received
- 0
- Value of contract
- to be confirmed
- Your guide to exporting
Description
Founded in 2001 in Yunnan province, the company is a modern biological pharmaceutical enterprise engaged in R&D and the production and sales of bio-medicine products. It is a National Validated High-tech Enterprise and Enterprise Technical Centre. Currently, the company has more than 1,000 employees, and owns a modern R & D centre in the local National High-tech Zone. It also has a modern vaccine production base and pilot base. The company has an extensive marketing network covering 30 provinces and cities in China.
Now the company is seeking cooperation with a UK company to produce or supply cellular immunity technology, i.e. the use of CAR-T cellular therapy technology, CAR-NK cellular therapy in tumor treatment, and to combine these technologies with anti-tumor drugs treatment.
To find out more, please register your interest with our team in China.
The China-Britain Business Council (‘CBBC’) is a membership organisation and UKTI’s chosen partner in China to deliver trade services. To find out more about CBBC please visit www.cbbc.org.
- Opportunity closing date
- 30 June 2016
- Value of contract
- to be confirmed
The deadline to apply for this opportunity has passed.
Visit the
opportunities page
to find another.